Guidelines for the management of bacterial and fungal infections during chemotherapy for pediatric acute leukemia or solid tumors: What is available in 2010?

Pediatric Reports

Volumn 3, Issue 1, 2011, Pages

  Castagnola, Elio ^a   Caviglia, Ilaria ^a   Haupt, Riccardo ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

Bacterial and fungal infections; Pediatric leukemia; Pediatric solid tumor

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; FLUCONAZOLE; ITRACONAZOLE; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; POSACONAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VORICONAZOLE;

ACUTE LEUKEMIA; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CATHETER INFECTION; CHILD; CHILD CARE; CHILD HEALTH CARE; COMBINATION CHEMOTHERAPY; DRUG INDICATION; FEBRILE NEUTROPENIA; HUMAN; INFECTION COMPLICATION; INFECTION CONTROL; INFECTION PREVENTION; LYMPHOMA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MONOTHERAPY; PRACTICE GUIDELINE; PSEUDOMONAS INFECTION; SECONDARY PREVENTION; SKIN INFECTION; SOFT TISSUE INFECTION; SOLID TUMOR; SYSTEMIC MYCOSIS;

EID: 83655196951     PISSN: None     EISSN: 20367503     Source Type: Journal    
DOI: 10.4081/pr.2011.e7     Document Type: Article

References (23)

1. Castagnola E, Boni L, Giacchino M, et al. A multicenter, randomized, double blind placebo-controlled trial of amoxicillin/ clavulanate for the prophylaxis of fever and infection in neutropenic children with cancer. Pediatr Infect Dis J 2003;22:359-65.
2. Maertens JA, Madero L, Reilly AF, et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 2010;29:415-20.
3. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51.
4. Milligan DW, Grimwade D, Cullis JO, et al. Guidelines on the management of acute myeloid leukaemia in adults. British Committee for Standards in Haematology. Br J Haematol 2006;135:450-74.
5. Cornely OA, Bohme A, Buchheidt D, et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 2009;94:113-22.
6. Bohme A, Ruhnke M, Buchheidt D, et al. Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009;88:97-110.
7. Neuburger S, Maschmeyer G. Update on management of infections in cancer and stem cell transplant patients. Ann Hematol 2006;85:345-56.
8. McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med 1997;126:71-720.
9. Sinclair JC, Cook RJ, Guyatt GH, et al. When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment. J Clin Epidemiol 2001; 54:253-62.
10. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005;142:979-95.
11. Leibovici L, Paul M, Cullen M, et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 2006;107:1743-51.
12. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. TN Engl J Med 2007;356:348-59.
13. Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008;46:1401-8.
14. Castagnola E, Caviglia I, Pistorio A, et al. Bloodstream infections and invasive mycoses in children undergoing acute leukaemia treatment: a 13-year experience at a single Italian institution. Eur J Cancer 2005;41:1439-45.
15. Castagnola E, Rossi MR, Cesaro S, et al. Incidence of bacteremias and invasive mycoses in children with acute non-lymphoblastic leukemia: Results from a multicenter Italian study. Pediatr Blood Cancer 2010;55:1103-7.
16. Hale KA, Shaw PJ, Dalla-Pozza L, et al. Epidemiology of paediatric invasive fungal infections and a case-control study of risk factors in acute leukaemia or post stem cell transplant. Br J Haematol 2010;149: 263-72.
17. Krishna G, Sansone-Parsons A, Martinho M, et al. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 2007;51:812-8.
18. Krishna G, Moton A, Ma L, et al. Pharma -cokinetics and absorption of posaconazole oral suspension under various gastric con-Article Non-commercial use only [page 24] [Pediatric Reports 2011; 3:e7] ditions in healthy volunteers. Antimicrob Agents Chemother 2009;53:958-66.
19. Dodds Ashley ES VJ, Krishna G, Vickery D, et al. Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. Antimicrob Agents Chemother 2009;53:2960-4.
20. Viscoli C, Castagnola E. Prophylaxis and Empirical Therapy of Infection in Cancer Patients. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. Philadelphia, Churchill Livingstone Elsevier, 2010; pp:3793-807.
21. Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009;48:1042-51.
22. Girmenia C, Micozzi A, Gentile G, et al. Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. J Clin Oncol 2010;28:667-74.
23. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005;41: 1242-50.